Conference Call with J B Chemicals & Pharmaceuticals Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company J B Chemicals & Pharmaceuticals announced Q3FY25 results Financial Highlights: JB Pharma recorded revenue of Rs 963 crore in the third quarter of FY25 registering growth of 14% from Rs 845 crore in Q3FY24. Operating EBITDA (Earnings before Interest Depreciation and Taxes) improved by 15% to Rs 270 crore. Profit after Taxes registered strong growth of 22% to Rs 162 crore vs Rs 134 crore in Q3FY24. Other Highlights: JB Pharma registered revenue of Rs 963 crore in Q3FY25 (YoY growth of 14%) and Rs 2969 crore in 9MFY25 (YoY growth of 13%). Domestic formulations business recorded revenue of Rs 566 crore vs Rs 462 crore (YoY growth of 22%). JB Pharma continues to remain one of the fastest growing companies in the industry. International business revenue grew by 4% at Rs 397 crore vs Rs 383 crore. CDMO business showed improved traction recording growth of 33% for Q3FY25. Domestic and CDMO business revenue combined constitutes 70% of overall revenue for 9MFY25. Operating EBITDA was Rs 270 crore in Q3FY25 (YoY growth of 15%) and Rs 846 crore in 9MFY25 (YoY growth of 16%). Operating EBITDA margin improved to 28.1% for Q3FY25 YoY and improved to 28.5% for 9MFY25 YoY. Gross margins were at 67.1% for Q3FY25 and 66.5% for 9MFY25. Excluding ophthalmology business, gross margins improved for Q3FY25 and 9MFY25. Cost optimization efforts, favorable product mix and price growth positively impacted gross margin. Other expenditure as percentage to sales improved to 22.7% in Q3FY25 v/s 23.2% in Q3FY24. Depreciation expenses remained the same as Q2FY25 at Rs 42 crore. Finance cost reduced to Rs 3 crore vs Rs 12 crore due to decrease in gross debt. Gross debt was Rs 54 crore and Net Cash was Rs 516 crore as on Dec 31, 2024. Net Profit improved by 22% YoY to Rs 162 crore vs Rs 134 crore. Nikhil Chopra, CEO and Wholetime Director, JB Pharma, said: “JB has delivered consistent growth over last few years even amidst a volatile macroeconomic environment. This has been enabled by our mix of businesses and markets, specifically our focus on India branded formulations, CDMO, and select international markets which play to our strengths, with limited revenues in countries that might present trade-related or economic volatility challenges. JB is well-positioned to deliver continued growth going forward as well. The strategy and levers are well-defined, and we have a strong team that will execute. Our India business continues to drive market beating growth led by chronic business and progressive portfolio within the acute segment. Our export business continues to be steady with sequential improvement witnessed in our CDMO business. While the growth run-rate of JB’s quarterly performance has been maintained, we have also improved our operating margins driven by product mix and efficiency initiatives. Advancement of various new projects in the CDMO business will flow through into growth numbers in the near to medium term, and we have a good pipeline of future product commercialization opportunities in international business which will deliver continued growth.” Result PDF
Conference Call with J B Chemicals & Pharmaceuticals Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.